MSQ: Migraine-Specific Quality-of-Life Questionnaire - Further investigation of the factor structure

被引:89
|
作者
Jhingran, P [1 ]
Davis, SM [1 ]
LaVange, LM [1 ]
Miller, DW [1 ]
Helms, RW [1 ]
机构
[1] Glaxo Wellcome Inc, Durham, NC 27709 USA
关键词
D O I
10.2165/00019053-199813060-00007
中图分类号
F [经济];
学科分类号
02 ;
摘要
MSQ, the 16-item Migraine-Specific Quality-of-Life Questionnaire (Version 1.0), was developed by Glare Wellcome Inc. to assess the effect of migraine and its treatment on patients' health-related quality of life (HR-QOL). The MSQ was hypothesised to measure 3 meaningful dimensions: (i) Role Function-Restrictive; (ii) Role Function-Preventive; and (iii) Emotional Function. The objective of this research was to further investigate the number of dimensions as well as the items contained in each dimension through principal components factor analysis of clinical trial data. Secondary objectives were to determine whether the factor structure changed in post-treatment visits compared with screening visits, to make recommendations for coding the MSQ when the patient did not have a migraine in the previous 4 weeks, and to modify the MSQ if so indicated by this research. Results supported the existence of 3 distinct factors which agreed strongly with the hypothesised dimensions. The analysis of post-treatment data suggested that the underlying factor structure of the MSQ varies as a result of treatment. Based on evaluations of the 'did not have a migraine' response, it was concluded that it be dropped from the MSQ. All these changes have been incorporated into MSQ (Version 2.0) which is being evaluated in studies to determine if its psychometric properties are different than the properties of the previous version.
引用
收藏
页码:707 / 717
页数:11
相关论文
共 50 条
  • [21] Migraine-specific quality of life questionnaire and relapse of medication overuse headache
    Stefano Caproni
    Elisa Bianchi
    Letizia M. Cupini
    Ilenia Corbelli
    Ettore Beghi
    Paolo Calabresi
    Paola Sarchielli
    BMC Neurology, 15
  • [22] Migraine-specific quality of life questionnaire and relapse of medication overuse headache
    Caproni, Stefano
    Bianchi, Elisa
    Cupini, Letizia M.
    Corbelli, Ilenia
    Beghi, Ettore
    Calabresi, Paolo
    Sarchielli, Paola
    BMC NEUROLOGY, 2015, 15
  • [23] Determinants of migraine-specific quality of life
    Santanello, N
    Davies, G
    Allen, C
    Kramer, M
    Lipton, R
    CEPHALALGIA, 2002, 22 (08) : 680 - 685
  • [24] Further development and testing of the migraine-specific quality of life (MSQOL) measure
    Patrick, DL
    Hurst, BC
    Hughes, J
    HEADACHE, 2000, 40 (07): : 550 - 560
  • [25] Further development and testing of a migraine-specific quality of life measure (MsQoL)
    Patrick, DL
    Hurst, BC
    NEUROLOGY, 1998, 50 (04) : A301 - A302
  • [26] Validity, reliability, and sensitivity to change of the Arabic version of the Migraine-Specific Quality-of-Life Questionnaire after prophylactic treatment
    Hussein, Mona
    Hassan, Amr
    Nada, Mona A. F.
    Mohammed, Zeinab
    Fathy, Wael
    Ghaffar, Nawal F. Abdel
    Kedah, Hanaa
    Magdy, Rehab
    HEADACHE, 2024,
  • [27] Validation of the Korean Migraine-Specific Quality of Life Questionnaire Version 2.1 in Episodic and Chronic Migraine
    Seo, Jong-Geun
    Park, Sung-Pa
    JOURNAL OF ORAL & FACIAL PAIN AND HEADACHE, 2017, 31 (03) : 251 - 256
  • [28] Validating Migraine-Specific Quality of Life Questionnaire v2.1 in Episodic and Chronic Migraine
    Bagley, Christine L.
    Rendas-Baum, Regina
    Maglinte, Gregory A.
    Yang, Min
    Varon, Sepideh F.
    Lee, Jeff
    Kosinski, Mark
    HEADACHE, 2012, 52 (03): : 409 - 421
  • [29] ITEM RESPONSE THEORY MODELING FRAMEWORK FOR EVALUATING MIGRAINE-SPECIFIC QUESTIONNAIRE (MSQ) IN MIGRAINE DRUG DEVELOPMENT.
    Chen, P.
    Pritchard-Bell, A.
    Karlsson, M.
    Ueckert, S.
    Davis, C.
    Nagase, M.
    Hsu, C.
    Dutta, S.
    Ahamadi, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S14 - S14
  • [30] Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients With Episodic Migraine by Galcanezumab Treatment: CGAN Japan Phase 2 Study
    Shibata, M.
    Nakamura, T.
    Kuga, A.
    Ozeki, A.
    Nichols, R. M.
    HEADACHE, 2020, 60 : 114 - 114